For protection from HIV-1 infection, more might not be better: A systematic analysis of HIV Gag epitopes of two alleles associated with different outcomes of HIV-1 infection

Journal of Virology

Volumn 86, Issue 2, 2012, Pages 1166-1180

  Luo, Ma ^a,b   Daniuk, Christina A ^a   Diallo, Tamsir O ^a   Capina, Rupert E ^a   Kimani, Joshua ^c   Wachihi, Charles ^c   Kimani, Makubo ^c   Bielawny, Thomas ^a   Peterson, Trevor ^a   Mendoza, Mark G R ^a   Kiazyk, Sandra ^a   Ball, T Blake ^a,b   Plummer, Francis A ^a,b  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; HLA ANTIGEN CLASS 1;

ALLELE; ARTICLE; BINDING AFFINITY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE FREQUENCY; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; KENYA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROSTITUTION;

ADULT; ALLELES; AMINO ACID SEQUENCE; COHORT STUDIES; EPITOPES, T-LYMPHOCYTE; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HLA ANTIGENS; HUMANS; KENYA; MOLECULAR SEQUENCE DATA; SEQUENCE ALIGNMENT; SEX WORKERS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84856913522     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05721-11     Document Type: Article

References (74)

1. Abrahams MR, et al. 2009. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J. Virol. 83:3556-3567.
2. Ahlers JD, Belyakov IM. Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS. Trends Immunol. 31:120-130.
3. AIDS Vaccine Advocacy Coalition. 2004. Support for the RV144 HIV vaccine trial. Science 305:177-180; author reply 177-180.
4. Alimonti JB, et al. 2006. Characterization of CD8 T-cell responses in HIV-1-exposed seronegative commercial sex workers from Nairobi, Kenya. Immunol. Cell Biol. 84:482-485.
5. Alimonti JB, et al. 2005. CD4+ T cell responses in HIV-exposed seronegative women are qualitatively distinct from those in HIV-infected women. J. Infect. Dis. 191:20-24.
6. Anonymous. 2003. AIDSVAX fails to prove efficacious in large-scale trial. Expert Rev. Vaccines 2:731.
7. Anonymous. 2007. HIV vaccine failure prompts Merck to halt trial. Nature 449:390.
8. Anonymous. 2008. NIAID declines to proceed with HIV vaccine trial. AIDS Policy Law 23:1, 4.
9. Anonymous. 2003. Results in for first phase III vaccine trial. AIDS Patient Care STDS 17:607-608.
10. Anonymous. 2007. Therapeutic vaccine trial shows no benefit. IAVI Rep. 11:20.
11. Anonymous. 2007. Vaccine trial discontinued. AIDS Patient Care STDS 21:778-779.
12. Bar KJ, et al. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J. Virol. 84:6241-6247.
13. Barouch DH, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat. Med. 16:319-323.
14. Bodinier M, et al. 2000. Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding. Nat. Med. 6:707-710.
15. Cohen J. 2009. HIV/AIDS research. Beyond Thailand: making sense of a qualified AIDS vaccine "success." Science 326:652-653.
16. Cohen J. 2009. HIV/AIDS research. Surprising AIDS vaccine success praised and pondered. Science 326:26-27.
17. Corey L, McElrath MJ. HIV vaccines: mosaic approach to virus diversity. Nat. Med. 16:268-270.
18. Emu B, et al. 2008. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J. Virol. 82:5398-5407.
19. Fischer W, et al. Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS One 5:e12303.
20. Fischer W, et al. 2007. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 13:100-106.
21. Fowke KR, et al. 1996. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 348:1347-1351.
22. Frahm N, et al. 2006. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat. Immunol. 7:173-178.
23. Friedrich TC, et al. 2007. Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication. J. Virol. 81: 3465-3476.
24. Friedrich TC, Watkins DI. 2008. Wanted: correlates of vaccine-induced protection against simian immunodeficiency virus. Curr. Opin. HIV AIDS 3:393-398.
25. Geldmacher C, et al. 2007. CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steadystate viremia in human immunodeficiency virus type 1-seropositive patients. J. Virol. 81:2440-2448.
26. Goulder PJ, Watkins DI. 2008. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat. Rev. Immunol. 8:619-630.
27. Hardie RA, et al. 2008. A common human leucocyte antigen-DP genotype is associated with resistance to HIV-1 infection in Kenyan sex workers. AIDS 22:2038-2042.
28. Hardie RA, et al. 2008. Human leukocyte antigen-DQ alleles and haplotypes and their associations with resistance and susceptibility to HIV-1 infection. AIDS 22:807-816.
29. Keele BF, et al. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105:7552-7557.
30. Kiepiela P, et al. 2007. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13:46-53.
31. Kong WP, et al. 2009. Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J. Virol. 83:2201-2215.
32. Kosmrlj A, et al. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature 465:350-354.
33. Kreiss JK, et al. 1986. AIDS virus infection in Nairobi prostitutes. Spread of the epidemic to East Africa. N. Engl. J. Med. 314:414-418.
34. Lacap PA, et al. 2008. Associations of human leukocyte antigen DRB with resistance or susceptibility to HIV-1 infection in the Pumwani Sex Worker Cohort. AIDS 22:1029-1038.
35. Land AM, et al. 2008. Full-length HIV type 1 proviral sequencing of 10 highly exposed women from Nairobi, Kenya reveals a high proportion of intersubtype recombinants. AIDS Res. Hum. Retroviruses 24:865-872.
36. Land AM, et al. 2008. High prevalence of genetically similar HIV-1 recombinants among infected sex workers in Nairobi, Kenya. AIDS Res. Hum. Retroviruses 24:1455-1460.
37. Leligdowicz A, et al. 2007. Robust Gag-specific T cell responses characterize viremia control in HIV-2 infection. J. Clin. Invest. 117:3067-3074.
38. Letourneau S, et al. 2007. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2:e984.
39. Li H, et al. High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog. 6:e1000890.
40. Liu J, et al. Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J. Virol. 84:10406-10412.
41. Luo M, et al. 2001. Two-step high resolution sequence-based HLA-DRB typing of exon 2 DNA with taxonomy-based sequence analysis allele assignment. Hum. Immunol. 62:1294-1310.
42. Luo M, Blanchard J, Pan Y, Brunham K, Brunham RC. 1999. Highresolution sequence typing of HLA-DQA1 and -DQB1 exon 2 DNA with taxonomy-based sequence analysis (TBSA) allele assignment. Tissue Antigens 54:69-82.
43. MacDonald KS, et al. 2000. Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. J. Infect. Dis. 181:1581-1589.
44. Maek ANW, et al. 2003. VaxGen vaccine trial fails the test but may offer insights. AIDS Alert 18:41-45.
45. McCarthy M. 2003. AIDS vaccine fails in Thai trial. Lancet 362:1728.
46. McCarthy M. 2003. HIV vaccine fails in phase 3 trial. Lancet 361:755-756.
47. Migueles SA, et al. 2000. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. U. S. A. 97:2709-2714.
48. Ojcius D. 2004. HIV vaccine trial halted. Nat. Rev. Microbiol. 2:776.
49. Ondondo BO, et al. 2008. Comprehensive analysis of HIV Gag-specific IFN-gamma response in HIV-1- and HIV-2-infected asymptomatic patients from a clinical cohort in The Gambia. Eur. J. Immunol. 38:3549-3560.
50. Peters HO, et al. 2008. An integrative bioinformatic approach for studying escape mutations in human immunodeficiency virus type 1 gag in the Pumwani Sex Worker Cohort. J. Virol. 82:1980-1992.
51. Plotkin SA. 2010. The RV144 Thai HIV vaccine trial. Hum. Vaccin. 6:159.
52. Plummer FA, Ball TB, Kimani J, Fowke KR. 1999. Resistance to HIV-1 infection among highly exposed sex workers in Nairobi: what mediates protection and why does it develop? Immunol. Lett. 66:27-34.
53. Riley JL, June CH. 2005. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 105:13-21.
54. Rolland M, et al. 2008. Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS One 3:e1424.
55. Rolland M, Nickle DC, Mullins JI. 2007. HIV-1 group M conserved elements vaccine. PLoS Pathog. 3:e157.
56. Rowland-Jones SL, et al. 2001. How important is the 'quality' of the cytotoxic T lymphocyte (CTL) response in protection against HIV infection? Immunol. Lett. 79:15-20.
57. Sacha JB, et al. 2007. Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J. Immunol. 178:2746-2754.
58. Saez-Cirion A, et al. 2009. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J. Immunol. 182:7828-7837.
59. Santra S, et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat. Med. 16:324-328.
60. Semeniuk CA, et al. 2010. Identification and characterization of HLAA* 0301 epitopes in HIV-1 gag proteins using a novel approach. J. Immunol. Methods 352:118-125.
61. Semeniuk CA, et al. 2009. Multiple T-cell epitopes overlap positivelyselected residues in the p1 spacer protein of HIV-1 gag. AIDS 23:771-777.
62. Serwanga J, et al. 2009. Host HLA B*allele-associated multi-clade Gag T-cell recognition correlates with slow HIV-1 disease progression in antiretroviral therapy-naive Ugandans. PLoS One 4:e4188.
63. Shingler WH, Chikoti P, Kingsman SM, Harrop R. 2008. Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4. Int. Immunol. 20:1057-1066.
64. Sidney J, et al. 2008. Quantitative peptide binding motifs for 19 human and mouseMHCclass I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res. 4:2.
65. Simonsen JN, et al. 1990. HIV infection among lower socioeconomic strata prostitutes in Nairobi. AIDS 4:139-144.
66. Streeck H, et al. 2009. Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J. Virol. 83:7641-7648.
67. Trachtenberg E, et al. 2003. Advantage of rare HLA supertype in HIV disease progression. Nat. Med. 9:928-935.
68. Trachtenberg EA, Erlich HA. 2001. A review of the role of the human leukocyte antigen (HLA) system as a host immunogenetic factor influencing HIV transmission and progression to AIDS, p I-43-I-60. In Korber BT, et al (ed), HIV Molecular Immunology 2001. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
69. Vaccari M, Poonam P, and Franchini G. 2010. Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. Expert Rev. Vaccines 9:997-1005.
70. Weiner DB. 18 February 2010. RV144: old vs. new. Hum. Vaccin. 6:159-161.
71. Wilson NA, et al. 2009. Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J. Virol. 83:6508-6521.
72. Wulf M, Hoehn P, Trinder P. 2009. Identification of human MHC class I binding peptides using the iTOPIA- epitope discovery system. Methods Mol. Biol. 524:361-367.
73. Yang OO. 2009. Candidate vaccine sequences to represent intra- and inter-clade HIV-1 variation. PLoS One 4:e7388.
74. Yang OO, Daar ES, Ng HL, Shih R, Jamieson BD. Increasing CTL targeting of conserved sequences during early HIV-1 infection is correlated to decreasing viremia. AIDS Res. Hum. Retroviruses 27:391-398.